Trivitron healthcare is a leading health technology manufacturer. The organization is committed to providing advanced health technology at best prices. Trivitron, as its primary response against the pandemic, has converged a major fraction of its resources and science to tackle the virus. Trivitron’s cutting edge technology and advanced research facilitates an application oriented development strategy with main focus on product design, quality control and solution based support. Navigating through the ongoing health crisis, Trivitron has initiated impactful research in the field of antibody testing.
An antibody test can detect if an individual has received exposure to SARS-CoV-2 or not and if a person has developed immunity against SARS-CoV-2 infection. Antibody tests are generally suitable for the development of a vaccine and for public health surveillance.
Trivitron’s efforts have resulted in COVIDscreen Plus , an ELISA based Total Antibody (IgG + IgM + IgA) detection kit for SARS-CoV-2.
What is it?
COVIDscreen Plus is a 100% indigenously developed kit developed by Trivitron Healthcare. The kit offers high value and is approved by the Indian Council of Medical Research and is validated by the National Institute of Virology (NIV). The kit is designed to be a vital component in the surveillance and diagnosis of the infection. COVIDscreen plus has a specificity of 99% and sensitivity of 100%
How it works?
COVIDscreen plus makes use of serum/plasma as sample. The sample is placed inside the small wells of the ELISA plate. The ELISA plates are coated with the antigen of COVID-19. If the sample is positive, i.e. it contains antibodies of the virus, then it binds with the antigen. Remaining reagents are added and the binding becomes visible as it produces a colour change, thus detecting COVID-19 antibodies.
Detection though COVIDscreen Plus
COVIDscreen Plus is an ELISA-based antibody detection test. This implies that the test commences with the detection of major Immunoglobulins types: Immunoglobulin G (IgG) Immunoglobulin M (IgM) and Immunoglobulin A (IgA). The body produces Immunoglobulins to fight against a pathogen. The IgA antibodies appear 2 days after the initial symptoms. The IgM antibodies are produced in four-seven days after pathogens enter the body while the IgG antibodies are produced between 10-14 days of the pathogen’s appearance. If the IgG antibody is detected, it can be concluded that the person was exposed to SARS-CoV-2.
COVIDscreen Plus offers a variety of advantages in comparison to almost all the available diagnostic kits in the market. The kit is portable, offers ease of application and is extremely sensitive and specific. COVIDscreen plus is the latest offering from Trivitron with features second to none, it reflects Trivitron’s scientific excellence, research capabilities and rock solid commitment.